Pharmaceutical Commerce
CONTINUE TO SITE >

OR WAIT 15 SECS

CDMO Regis Technologies doubles its capacity

February 18, 2021

Lab development project features 9,000-square-foot expansion

Regis Technologies, Inc., a contract development and manufacturing organization (CDMO), announced the completion of a 9,000-square-foot expansion of its laboratory facilities for the development of active pharmaceutical ingredients (APIs). The Morton Grove, IL-expansion doubles the company’s capacity to take on new development projects, and is now fully operational. It increases capabilities across Regis’ custom pharmaceutical service offerings, including analytical development, process chemistry, solid state chemistry, validation, stability studies and commercialization.

Regis’ focus is in serving the API development and manufacturing needs of mid-sized and emerging pharma and biotech companies. The plan to grow the lab was launched two years ago.

The expansion features additional process chemistry and analytical laboratories, an ICP-MS (inductively coupled plasma mass spectrometry) suite, supplementary climate-controlled storage, 14 additional fume hoods, several new kilo-scale reactors, and process safety equipment for reaction calorimetry measurements to ensure safe control and scale-up. The new laboratories, Regis says, also have an advanced variable air volume (VAV) air system for clean energy-efficient operations.